Document 3275
 DOCN  M94A3275
 TI    HIV-1 V3-loop antibodies and it's association with clinical status in
       Nairobi.
 DT    9412
 AU    Songok M; Tukei P; Mulaa FJ; Kenya Medical Research Institute, Nairobi.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):113 (abstract no. PA0070). Unique
       Identifier : AIDSLINE ICA10/94369300
 AB    In our bid to determine the HIV-1 variants in transmission in Nairobi
       and their association with clinical status and infectivity, we screened
       by ELISA two hundred and seven (207) confirmed HIV positive patients
       visiting our HIV/AIDS clinic in Nairobi between June 1993 and January
       1994. We used a panel of HIV-1 V3 loop peptides (ANRS, France) derived
       from seven isolates.: MN,HXB2,SC,Z6,Z2,ELI and CDC4. Test samples were
       obtained from blood donors (42), high school students (53) Patients with
       diarrhoea (26) herpes Zoster (16) oral thrush (11) lympadenopathy (12)
       PTB (19) and weight loss (28). 21.5% had antibodies against the MN
       strain; 19.1% had against Z2 strain while reaction against the HXB2
       strain was observed in 17.2%. SC,CDC4, Z6, and ELI had prevalence of
       11.5%, 6.2%, 5.3% and 3.8% respectively. 14.8% of the tested sera showed
       no reaction to any of the used peptides. Anti-HXB2 antibodies were
       strongly and significantly associated with an asymptomatic state (P >
       0.01). We infer that both North American (MN,HXB2) and subsaharan
       isolates (Z2) are highly prevalent in Nairobi. There is evidence that
       particular variants are associated with asymptomatic state and needs
       further investigation. Thirdly, the use of synthetic peptides
       representing the V3 epitope may be an easier and sensitive way in the
       broad determination of antigenic diversity.
 DE    Human  HIV Antibodies/*BLOOD  HIV Envelope Protein
       gp120/*GENETICS/*IMMUNOLOGY  HIV
       Infections/EPIDEMIOLOGY/*IMMUNOLOGY/MICROBIOLOGY
       HIV-1/*GENETICS/*IMMUNOLOGY/ISOLATION & PURIF  Kenya/EPIDEMIOLOGY
       Peptide Fragments/*GENETICS/*IMMUNOLOGY  Peptides/IMMUNOLOGY  Species
       Specificity  Variation (Genetics)  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).